An oesophageal and pulmonary association not to forget

Sunwoo, Bernie Y.

doi:10.1136/thoraxjnl-2016-209045

Cited by 2 publications

(1 citation statement)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2007 official American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) statement showed that M. fortuitum isolates were susceptible to amikacin (100%), ciprofloxacin and ofloxacin (100%), sulfonamides (100%), cefoxitin (50%), imipenem (100%), clarithromycin (80%), and doxycycline (50%) [4]. Several previous cases have reported that combining antibiotics, including quinolones, successfully completed the treatment [5,6]. There is no report about the treatment of resistant M. fortuitum.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report

et al. 2020

View full text Add to dashboard Cite

Background Mycolicibacterium fortuitum is a species of the rapidly growing mycobacteria that can cause pulmonary infection. It is susceptible to multiple antibiotics both in vitro and in clinical practice, so that any combination of susceptible drugs is effective. However, we encountered a case of infection due to fluoroquinolone-resistant M. fortuitum. In this study, we report the case and describe the mechanism of resistance. Case presentation A 65-year-old man with a history of total gastrectomy and immunosuppressant treatment for rheumatoid arthritis developed a recurrence of pulmonary infection caused by M. fortuitum. He was treated with clarithromycin and levofloxacin as a first-line treatment, based on the favorable susceptibility at that time. After recurrence, a high minimum inhibitory concentration to fluoroquinolones was detected. DNA sequencing of the pathogen showed the substitution of serine for tryptophan at residue 83 in the gyrA gene. He was successfully treated with a combination of other antibiotics. Conclusion This is the first report on the treatment of fluoroquinolone-resistant M. fortuitum and investigation of the mechanism of resistance. We suggest that the susceptibility test remains effective for determining the next line of treatment after a pathogen has acquired resistance, and resistance to fluoroquinolones in M. fortuitum can be attributed to a single change of amino acid.

show abstract

Section: Introductionmentioning

confidence: 99%

Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report

et al. 2020

View full text Add to dashboard Cite

show abstract

Mycobacterium septicum: a 6-Year Clinical Experience from a Tertiary Hospital and Reference Laboratory

Wengenack

Saleh

et al. 2020

J Clin Microbiol

View full text Add to dashboard Cite

Mycobacterium septicum is a rarely identified nontuberculous mycobacterium capable of causing infections in both healthy and immunocompromised individuals. Only a few cases of M. septicum infections have been reported, which makes recognizing corresponding clinical disease more challenging for clinicians. Antimicrobial susceptibility profiles for this organism are not well described, and corresponding optimal therapeutic regimens have not been established. We report a tertiary care center's experience with M. septicum from 2014 to 2020. Twelve adult patients with positive cultures for M. septicum were identified. Most cases were identified from sputum samples of individuals with underlying lung disease. Most cases involving M. septicum isolation in culture were not felt to be clinically significant. Two cases were considered possible infections while only one case was considered a definite infection that required antimicrobial treatment. All M. septicum isolates were susceptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole. Isolates were universally resistant to clarithromycin and doxycycline. The isolation of M. septicum in culture is uncommon and requires clinical correlation to determine its clinical relevance and need for treatment. Susceptibility testing should be performed to guide therapy.

show abstract

An oesophageal and pulmonary association not to forget

Cited by 2 publications

References 7 publications

Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report

Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report

Mycobacterium septicum: a 6-Year Clinical Experience from a Tertiary Hospital and Reference Laboratory

Contact Info

Product

Resources

About